On February 20, the China Association for Science and Technology (CAST) officially released the results of its 2022 "Innovation China" series roster. Following multiple rounds of rigorous evaluation, Beijing tricision Biotech Co., Ltd. (tricision) was selected for the Pioneering Technology Roster, underscoring the Company's top-tier research capabilities in frontier biotechnology.

The "Innovation China" roster, launched by CAST, is a flagship initiative designed to identify and promote transformative technologies that can drive high-quality development. It serves as a barometer for innovation, aligning with national strategic priorities and fostering deep integration between the innovation chain and industrial ecosystems. The roster comprises seven categories, with the Biomedicine category specifically targeting technologies that address critical bottlenecks, fill domestic gaps, demonstrate breakthrough potential, and offer strong commercial viability. Selected technologies are expected to be transferable, scalable, and capable of contributing to technological self-reliance.

tricision was recognized for its project "Development and Industrialization of Lyophilized Dosage Form of mRNA Vaccine Lipid Nanoparticle (LNP) Vectors"—making it the only mRNA technology selected in the Biomedicine category.

The lyophilized Messenger RNA-Lipid Nanoparticle (mRNA-LNP) vaccine platform employs a proprietary LNP delivery system that significantly enhances vaccine stability and shelf life. Multiple Chinese invention patents and Patent Cooperation Treaty (PCT) international applications have been filed. The platform's applications span prophylactic vaccines, tumor immunotherapy, protein replacement therapy, and regenerative medicine. Notably, the vaccine demonstrates at least 6 months of stability at 2–8°C or -80°C ± 10°C, enabling storage and transport under standard cold-chain conditions—a major improvement over current requirements and a critical enabler for broader vaccine access.

The technology has already been translated into tricision's mRNA vaccine candidate against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variants with cross-protective effects. The vaccine formulation has received a pre-registration inspection report from the National Institutes for Food and Drug Control (NIFDC), and a Clinical Trial Application (CTA) has been submitted to the National Medical Products Administration (NMPA).

tricision's research team is leveraging this recognition to further drive innovation in mRNA technology, with a focus on localized R&D, manufacturing, and commercialization to meet the growing domestic and global demand for advanced mRNA vaccines and therapeutics. The Company aims to use this momentum to accelerate technological innovation, address economic challenges, and deliver tangible social impact—demonstrating the value of science-driven solutions in public health.